Tough times for Tecentriq as NICE once again slaps down Roche's immunotherapy — slight benefit not worth price
The UK drug-pricing watchdog has again nixed Roche and its cancer immunotherapy Tecentriq.
The National Institute for Health and Care Excellence’s latest filing is for extensive-stage small cell lung cancer patients. The regulator determined that although Tecentriq appeared to improve patient survival and quality of life in clinical trials, that data was uncertain and based on patients who were dissimilar to the average NHS patient. The benefits Roche had shown were not worth the drug’s on average £32,800 (roughly $43,300) price, NICE said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.